Inactive Instrument

OpGen Inc Stock Nasdaq

Equities

US68373L1098

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2021 4.31M 5.89M Sales 2022 2.61M 3.57M Capitalization 7.57M 10.36M
Net income 2021 -34M -46.53M Net income 2022 -37M -50.63M EV / Sales 2021 6.51 x
Net cash position 2021 10.9M 14.92M Net Debt 2022 7.38M 10.1M EV / Sales 2022 5.74 x
P/E ratio 2021
-0.87 x
P/E ratio 2022
-0.18 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 60 21-12-31
Chief Operating Officer 55 20-03-31
Corporate Officer/Principal 53 20-03-31
Members of the board TitleAgeSince
Corporate Officer/Principal 53 20-03-31
More insiders
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW